Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1297

Similar articles for PubMed (Select 15721375)

1.

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.

Methods Enzymol. 2005;391:71-97.

PMID:
15721375
4.

Liposomal doxorubicin.

Tardi PG, Boman NL, Cullis PR.

J Drug Target. 1996;4(3):129-40. Review.

PMID:
8959485
5.
7.

The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.

Mayer LD, Dougherty G, Harasym TO, Bally MB.

J Pharmacol Exp Ther. 1997 Mar;280(3):1406-14.

8.

Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?

Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.

J Control Release. 2007 Apr 2;118(2):204-15. Epub 2006 Dec 8.

PMID:
17239468
10.

Liposomes in the treatment of malignancy: a clinical perspective.

Sugarman SM, Perez-Soler R.

Crit Rev Oncol Hematol. 1992;12(3):231-42. Review.

PMID:
1497823
11.

Entrapment of small molecules and nucleic acid-based drugs in liposomes.

Fenske DB, Cullis PR.

Methods Enzymol. 2005;391:7-40.

PMID:
15721372
12.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
13.
14.

[Polymer and oligomer based doxorubicin carriers].

Kik K, Lwow F, Szmigiero L.

Polim Med. 2007;37(1):47-55. Review. Polish.

PMID:
17703723
15.

New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.

Tinkov S, Winter G, Coester C, Bekeredjian R.

J Control Release. 2010 Apr 2;143(1):143-50. doi: 10.1016/j.jconrel.2009.12.026. Epub 2010 Jan 11.

PMID:
20060861
16.

Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.

Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q.

Pharm Res. 2005 Jun;22(6):933-9. Epub 2005 Jun 8.

PMID:
15948037
17.

Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.

Allen TM, Cheng WW, Hare JI, Laginha KM.

Anticancer Agents Med Chem. 2006 Nov;6(6):513-23. Review.

PMID:
17100556
18.

Use of liposomes as injectable-drug delivery systems.

Ostro MJ, Cullis PR.

Am J Hosp Pharm. 1989 Aug;46(8):1576-87. Review.

PMID:
2672806
20.

A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.

Papagiannaros A, Hatziantoniou S, Dimas K, Papaioannou GT, Demetzos C.

Biomed Pharmacother. 2006 Jan;60(1):36-42. Epub 2005 Oct 25.

PMID:
16271845
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk